UTHR Related Analyst Ratings
-
Standpoint Research Downgrades United Therapeutics Corp. (UTHR) to Hold
-
Ladenburg Thalmann Downgrades United Therapeutics Corp. (UTHR) to Neutral
-
Brean Downgrades United Therapeutics (UTHR) to Hold, Says Price Target Acheived
-
Standpoint Research Upgrades United Therapeutics Corp. (UTHR) to Buy
-
Guggenheim Starts United Therapeutics Corp. (UTHR) at Neutral
-
Goldman Sachs Downgrades United Therapeutics Corp. (UTHR) to Sell
-
JPMorgan Downgrades United Therapeutics Corp. (UTHR) to Underweight
-
BMO Capital Downgrades United Therapeutics Corp. (UTHR) to Market Perform
-
Standpoint Research Downgrades United Therapeutics Corp. (UTHR) to Hold
-
Canaccord Genuity Maintains a 'Hold' on United Therapeutics (UTHR); Increasing FY12 Adcirca and Tyvaso Revenues
-
UPDATE - Canaccord Genuity Downgraded United Therapeutics (UTHR) to Hold; Sidelined on Uncertainty
-
Canaccord Genuity Downgrades United Therapeutics Corp. (UTHR) to Hold
-
Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect
-
Leerink Swann Downgrades United Therapeutics Corp. (UTHR) to Market Perform; Generic Risk
-
Canaccord Genuity Starts United Therapeutics Corp. (UTHR) at Buy
-
Standpoint Research Starts United Therapeutics Corp. (UTHR) at Buy
-
Auriga Maintains a 'Hold' on United Therapeutics (UTHR); Q4 Review
-
United Therapeutics (UTHR) Lower As Analyst Highlights Sandoz Generic Remodulin Filing
-
Short Interest Ticks Up in Large-Cap Biotech, Specifically Amgen (AMGN)
-
Goldman Sachs Downgrades United Therapeutics Corp. (UTHR) to Neutral
-
Goldman Sachs Upgrades Onyx Pharmaceuticals (ONXX) to Buy
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform
-
Maxim Group Downgrades United Therapeutics Corp. (UTHR) to Hold
-
Goldman Sachs Cuts Price Target on United Therapeutics (UTHR), But Still Sees 30% Upside
-
Citi Downgrades United Therapeutics Corp. (UTHR) to Hold
-
Auriga Downgrades United Therapeutics Corp. (UTHR) to Hold; FREEDOM-C2 Fails To Hit Primary Endpoint
-
Citi Cuts United Therapeutics Corp. (UTHR) to Hold
-
JPMorgan Downgrades United Therapeutics Corp. (UTHR) to Neutral
-
Deutsche Bank Downgrades United Therapeutics Corp. (UTHR) to Hold; Oral Approval Likelihood Lowered
-
Goldman Sachs Sees Heavy Upside in United Therapeutics (UTHR) With Limited Risk
-
Citadel Securities Maintains a 'Neutral' on United Therapeutics (UTHR); Tyvaso Growth Returns, but We Remain Cautious Ahead of FREEDOM-C2 Data
-
Needham & Company Maintains a 'Buy' on Pluristem Therapeutics (PSTI); Enters into Early-Stage Licensing Agreement Around PLX Cells
-
RBC Capital Downgrades United Therapeutics Corp. (UTHR) to Sector Perform
-
Citadel Securities Downgrades United Therapeutics Corp. (UTHR) to Neutral
-
Citadel Securities Upgrades United Therapeutics Corp. (UTHR) to Add on Statistical, pK Analysis of FREEDOM-M
-
Auriga Starts United Therapeutics Corp. (UTHR) at Buy
-
UPDATE: Wedbush Upgrades United Therapeutics (UTHR) to Outperform, Raises Fair Value Estimate to $94
-
United Therapeutics (UTHR) Shares Edge Higher as Wedbush Upgrades to Outperform
-
Citadel Securities Starts United Therapeutics Corp. (UTHR) at Neutral, Anticipating FREEDOM-M Outcome
-
Deutsche Bank Starts United Therapeutics Corp. (UTHR) at Buy; Attractive Risk/Reward into FREEDOM M
-
Stifel Nicolaus Starts United Therapeutics Corp. (UTHR) at Buy
-
Goldman Sachs Starts United Therapeutics Corp. (UTHR) at Buy, Sees 25% Upside
-
Credit Suisse Initiates Coverage on HGSI, EXAM, UTHR, BIIB, CELG, GILD, AMGN, LH
-
Leerink Swann Says M&A Is One Reason To Get Involved In Biophama (AGN, DNDN, BMRN, HGSI, more...)
-
Citi 2Q10 SMID Biotech Earnings Preview: Adjusting AUXL & DNDN Models Ahead of Earnings; Top-Pick is BioMarin (BMRN)
-
J.P. Morgan Upgrades United Therapeutics (UTHR) to Overweight
-
Auriga Maintains Positive Stance On United Therapeutics (UTHR) Citing Strong Tyvaso Uptake
-
Summer Street Upgrades United Therapeutics (UTHR) to Buy; Evidence of Continued Strong Tyvaso Rollout
-
Auriga Maintains a 'Buy' on United Therapeutics (UTHR); Named as Best 2010 Biotechnology Idea
-
Wedbush Maintains a 'Neutral' on United Therapeutics (UTHR); Raises PT & Estimates
Back to UTHR Stock Lookup
